{"url_path":"/sec/vate/8-k/2026-02-10/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-02-10","source_url":"https://www.sec.gov/Archives/edgar/data/1006837/0001006837-26-000005-index.html","accession_number":"0001006837-26-000005","cik":"0001006837","ticker":"VATE","issuer_name":"INNOVATE Corp.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1006837/0001006837-26-000005-index.html","primary_entity_key":"0001006837","primary_entity_name":"INNOVATE Corp."},"word_count":105,"has_tables":true,"body_markdown":"Item 9.01Financial Statements and Exhibits.\n\n(d)    Exhibits\n\nExhibit No.  \n\n Description\n\n99.1\n[Press Release dated February](a202602108-kxexhibit991.htm)[10](a202602108-kxexhibit991.htm)[, 2026, titled “Transdermal GFR Article Recognized as One of Five 2025 Editors’ Choice Articles by Journal of the American Society of Neph](a202602108-kxexhibit991.htm)[r](a202602108-kxexhibit991.htm)[ology (JASN)”](a202602108-kxexhibit991.htm)\n\n104Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nDate: February 10, 2026\n\nINNOVATE Corp. (Registrant)\n\nBy:/s/ Michael J. Sena\n\nName: Michael J. Sena\n\nTitle: Chief Financial Officer"}